Processa Pharmaceuticals Announces FDA Clearance Of IND Application For A Phase 2 Clinical Trial Of NGC-Cap In Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Processa Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase 2 clinical trial of NGC-Cap in breast cancer. The trial will start this quarter with initial data expected by mid-2025.
July 30, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Processa Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase 2 clinical trial of NGC-Cap in breast cancer. The trial will start this quarter with initial data expected by mid-2025.
FDA clearance for a Phase 2 clinical trial is a significant milestone for Processa Pharmaceuticals, indicating regulatory progress and potential future revenue. This news is likely to positively impact the stock price in the short term as it demonstrates advancement in their product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100